Applications of Liquid Biopsy in the Pharmacological Audit Trail for Anticancer Drug Development

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2021 Mar 25

PMID 33762744

Citations 8

Authors

Abhijit Pal

Rajiv Shinde

Manuel Selvi Miralles

Paul Workman

Johann de Bono

Affiliations

Soon will be listed here.

Abstract

Anticancer drug development is a costly and protracted activity, and failure at late phases of clinical testing is common. We have previously proposed the Pharmacological Audit Trail (PhAT) intended to improve the efficiency of drug development, with a focus on the use of tumour tissue-based biomarkers. Blood-based 'liquid biopsy' approaches, such as targeted or whole-genome sequencing studies of plasma circulating cell-free tumour DNA (ctDNA) and circulating tumour cells (CTCs), are of increasing relevance to this drug development paradigm. Liquid biopsy assays can provide quantitative and qualitative data on prognostic, predictive, pharmacodynamic and clinical response biomarkers, and can also enable the characterization of disease evolution and resistance mechanisms. In this Perspective, we examine the promise of integrating liquid biopsy analyses into the PhAT, focusing on the current evidence, advances, limitations and challenges. We emphasize the continued importance of analytical validation and clinical qualification of circulating tumour biomarkers through prospective clinical trials.

Citing Articles

A drug-mediated organic electrochemical transistor for robustly reusable biosensors.

Jiang Z, Ye D, Xiang L, He Z, Dai X, Yang J Nat Mater. 2024; 23(11):1547-1555.

PMID: 39112738 DOI: 10.1038/s41563-024-01970-5.

Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms.

Majumder B, Nataraj N, Maitreyi L, Datta S Front Immunol. 2024; 15:1414376.

PMID: 39100682 PMC: 11294168. DOI: 10.3389/fimmu.2024.1414376.

The development of a novel zeolite-based assay for efficient and deep plasma proteomic profiling.

Li N, Huang J, He S, Zheng Q, Ye F, Qin Z J Nanobiotechnology. 2024; 22(1):164.

PMID: 38600601 PMC: 11007927. DOI: 10.1186/s12951-024-02404-9.

Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development.

Gao W, Liu J, Shtylla B, Venkatakrishnan K, Yin D, Shah M CPT Pharmacometrics Syst Pharmacol. 2023; 13(5):691-709.

PMID: 37969061 PMC: 11098159. DOI: 10.1002/psp4.13079.

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC.

Jie G, Peng L, Zheng M, Sun H, Wang S, Liu S Cancers (Basel). 2023; 15(1).

PMID: 36612298 PMC: 9818927. DOI: 10.3390/cancers15010302.

References

Sharpe E, Hoey R, Yap C, Workman P . From patent to patient: analysing access to innovative cancer drugs. Drug Discov Today. 2020; 25(9):1561-1568. DOI: 10.1016/j.drudis.2020.01.004. View

Workman P, Draetta G, Schellens J, Bernards R . How Much Longer Will We Put Up With $100,000 Cancer Drugs?. Cell. 2017; 168(4):579-583. DOI: 10.1016/j.cell.2017.01.034. View

Yap T, Sandhu S, Workman P, de Bono J . Envisioning the future of early anticancer drug development. Nat Rev Cancer. 2010; 10(7):514-23. DOI: 10.1038/nrc2870. View

Workman P . Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther. 2003; 2(2):131-8. View

Banerji U, ODonnell A, Scurr M, Pacey S, Stapleton S, Asad Y . Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol. 2005; 23(18):4152-61. DOI: 10.1200/JCO.2005.00.612. View

Attard G, Reid A, Yap T, Raynaud F, Dowsett M, Settatree S . Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008; 26(28):4563-71. DOI: 10.1200/JCO.2007.15.9749. View

Attard G, Reid A, AHern R, Parker C, Oommen N, Folkerd E . Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009; 27(23):3742-8. PMC: 3535569. DOI: 10.1200/JCO.2008.20.0642. View

Fong P, Boss D, Yap T, Tutt A, Wu P, Mergui-Roelvink M . Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2):123-34. DOI: 10.1056/NEJMoa0900212. View

Sarker D, Ang J, Baird R, Kristeleit R, Shah K, Moreno V . First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2014; 21(1):77-86. PMC: 4287394. DOI: 10.1158/1078-0432.CCR-14-0947. View

10.

Raynaud F, Eccles S, Patel S, Alix S, Box G, Chuckowree I . Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009; 8(7):1725-38. PMC: 2718129. DOI: 10.1158/1535-7163.MCT-08-1200. View

11.

Carden C, Banerji U, Kaye S, Workman P, de Bono J . From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin Pharmacol Ther. 2009; 85(2):131-3. DOI: 10.1038/clpt.2008.223. View

12.

Carden C, Sarker D, Postel-Vinay S, Yap T, Attard G, Banerji U . Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. Drug Discov Today. 2009; 15(3-4):88-97. DOI: 10.1016/j.drudis.2009.11.006. View

13.

de Bono J, De Giorgi U, Nava Rodrigues D, Massard C, Bracarda S, Font A . Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clin Cancer Res. 2018; 25(3):928-936. DOI: 10.1158/1078-0432.CCR-18-0981. View

14.

Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P . PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol. 2014; 67(4):795-802. PMC: 4410287. DOI: 10.1016/j.eururo.2014.10.027. View

15.

Biondo A, Pal A, Riisnaes R, Shinde R, Tiu C, Lockie F . Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience. Cancer Treat Res Commun. 2021; 27:100309. DOI: 10.1016/j.ctarc.2021.100309. View

16.

Perez-Lopez R, Mateo J, Mossop H, Blackledge M, Collins D, Rata M . Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology. 2016; 283(1):168-177. PMC: 6140995. DOI: 10.1148/radiol.2016160646. View

17.

Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S . Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discov. 2017; 7(9):1006-1017. PMC: 6143169. DOI: 10.1158/2159-8290.CD-17-0261. View

18.

Attard G, Swennenhuis J, Olmos D, Reid A, Vickers E, AHern R . Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009; 69(7):2912-8. DOI: 10.1158/0008-5472.CAN-08-3667. View

19.

Banerji U, Workman P . Critical parameters in targeted drug development: the pharmacological audit trail. Semin Oncol. 2016; 43(4):436-45. DOI: 10.1053/j.seminoncol.2016.06.001. View

20.

Takimoto C . Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development. Eur J Cancer. 2009; 45 Suppl 1:436-8. DOI: 10.1016/S0959-8049(09)70080-2. View